Comparative Analysis and Benchmarking: Corporate Strategy Analysis of Four International Pharmaceutical Companies
This research of corporate strategy analysis implements comparative analysis and benchmarking to analyse and examine the corporate strategy of the pharmaceutical sectors of 4 international pharmaceutical companies. This research adopts the hybrid approach of combining qualitative and quantitative methods in a two stages research design. Quantitative method is applied first to deal with the comparative figures, and then qualitative method is used to find out the problem. The design of this multiple research includes three phases: data collection, analysis, and reporting. The findings of this research can be divided into 4 parts: R&D/marketing, technology alliances, strategic acquisitions and merger, and manufacturing. The drug innovative projects are recommended being developed within the company's familiar therapeutic areas in order to take its marketing advantage. Through this comparative analysis, some of this type of problems of these international pharmaceutical companies is identified. A big pharmaceutical company forming alliances with some small biotechnology companies has become a trend within pharmaceutical industry since 1980s. For pharmaceutical companies, to take advantage of R&D through biotechnology is the main purpose of alliances with small biotechnology companies. It is important to note that most pharmaceutical acquisitions belong to the type of absorption with high resource transferring and low autonomy. Due to the high profit margin and the essential importance of R&D and marketing, the operation management of manufacturing of pharmaceutical industry is relatively poor. The low asset utilisation rate pointed out this problem. Academic researches have revealed that existing theories of operation management of manufacturing, such as action research, set-up reduction, teamwork, continuous improvement, collaboration, and involvement, are applicable and beneficial to pharmaceutical industry rather than waiting for the technology breakthroughs.
What people are saying - Write a review
We haven't found any reviews in the usual places.
acquisitions Aerospace alliances analyse the corporate analysis and benchmarking Ansoff Matrix Anti-bacteria Anti-virus Augmentin Automotive British pharmaceutical industry British Sterling Business Publication 1998 cardiovascular combinatorial chemistry comparative analysis comparative figures Comparison of turnover Comparisons of R&D competition competitors corporate strategy cost Dermatology dissertation drug innovation existing market existing theories Gastro-intestine Glaxo Wellcome Global pharmaceutical markets GW SB Zeneca healthcare Historical Analysis ICC Business Publication identified Immunology implemented IMS Health innovation projects Inter-company Comparison international pharmaceutical companies Johnson & Johnson key products Mach management of manufacturing market share million in 1997 million Novartis GW Novartis GW SB NSAID oncology operation management organisation pharmaceutical price regulation Product development pipeline qualitative R&D and marketing R&D expenditure R&D Investment R&D/marketing interface Related technology respiratory sales amount small biotechnology companies SmithKline Beecham Source Table technology and existing technology breakthrough technology environment therapeutic area turnover by therapeutic Unrelated technology Wang Warwick Manufacturing Group Wellcome's Zantac